JP2013534535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534535A5 JP2013534535A5 JP2013519199A JP2013519199A JP2013534535A5 JP 2013534535 A5 JP2013534535 A5 JP 2013534535A5 JP 2013519199 A JP2013519199 A JP 2013519199A JP 2013519199 A JP2013519199 A JP 2013519199A JP 2013534535 A5 JP2013534535 A5 JP 2013534535A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- disease
- lymphoma
- sclc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000003026 hypopharynx Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 206010061311 nervous system neoplasm Diseases 0.000 claims 1
- 210000003300 oropharynx Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 210000002936 ureteral cell Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36350710P | 2010-07-12 | 2010-07-12 | |
| US61/363,507 | 2010-07-12 | ||
| PCT/IB2011/053092 WO2012007896A1 (en) | 2010-07-12 | 2011-07-11 | Multifunctional antibody conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015248537A Division JP6339995B2 (ja) | 2010-07-12 | 2015-12-21 | 多機能性抗体複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534535A JP2013534535A (ja) | 2013-09-05 |
| JP2013534535A5 true JP2013534535A5 (cg-RX-API-DMAC7.html) | 2014-03-20 |
| JP5913307B2 JP5913307B2 (ja) | 2016-04-27 |
Family
ID=44630490
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519199A Active JP5913307B2 (ja) | 2010-07-12 | 2011-07-11 | 多機能性抗体複合体 |
| JP2015248537A Active JP6339995B2 (ja) | 2010-07-12 | 2015-12-21 | 多機能性抗体複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015248537A Active JP6339995B2 (ja) | 2010-07-12 | 2015-12-21 | 多機能性抗体複合体 |
Country Status (19)
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2815967A1 (en) * | 2010-11-05 | 2012-05-10 | Covx Technologies Ireland Limited | Anti-diabetic compounds |
| EA029797B1 (ru) * | 2011-06-21 | 2018-05-31 | Иммуноджен, Инк. | Новые производные майтанзиноида с пептидным линкером и их конъюгаты |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| TW201341401A (zh) * | 2012-01-09 | 2013-10-16 | Covx Technologies Ireland Ltd | 突變抗體及其共軛 |
| WO2014057687A1 (ja) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | 抗体－薬物コンジュゲート |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| CA2890256A1 (en) | 2012-11-07 | 2014-05-15 | Pfizer Inc. | Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates |
| TW201431880A (zh) | 2012-11-07 | 2014-08-16 | Pfizer | 抗切口３（ａｎｔｉ－ｎｏｔｃｈ３）抗體及抗體－藥物共軛體 |
| BR112015010360A8 (pt) | 2012-11-08 | 2018-01-16 | Eleven Biotherapeutics Inc | antagonistas de il-6 e utilização dos mesmos. |
| AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| EP2935608A1 (en) * | 2013-10-14 | 2015-10-28 | SynAffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| EP3929301A1 (en) * | 2013-10-14 | 2021-12-29 | SynAffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| SI3424955T1 (sl) | 2013-12-25 | 2025-08-29 | Daiichi Sankyo Company, Limited | Metoda za proizvodnjo konjugata protitelo-zdravilo anti-trop2 |
| SI3101032T1 (sl) * | 2014-01-31 | 2019-02-28 | Daiichi Sankyo Company, Limited | Konjugat zdravila s protitelesci ANTI-HER2 |
| PT3122757T (pt) | 2014-02-28 | 2023-11-03 | Hangzhou Dac Biotech Co Ltd | Ligantes carregados e as suas utilizações em conjugação |
| SMT202500021T1 (it) | 2014-04-10 | 2025-03-12 | Daiichi Sankyo Co Ltd | Metodo per produrre un coniugato anticorpo anti-her3-farmaco |
| JP6612738B2 (ja) | 2014-04-10 | 2019-11-27 | 第一三共株式会社 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| UA122673C2 (uk) | 2014-11-07 | 2020-12-28 | Елевен Байотерапьютікс, Інк. | Антитіло, що специфічно зв'язується з людським il-6 |
| TWI614023B (zh) * | 2015-05-20 | 2018-02-11 | 免疫功坊股份有限公司 | 具有標的部分及效應部分的胜肽核多臂接合物 |
| DK3795591T5 (da) * | 2015-06-19 | 2024-08-19 | Eisai R&D Man Co Ltd | Cys80-konjugerede immunoglobuliner |
| US11173213B2 (en) | 2015-06-29 | 2021-11-16 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| JP2018527350A (ja) * | 2015-09-01 | 2018-09-20 | イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． | 血餅形成の予防及び／又は血栓症の治療のための分子構築物 |
| US11197934B2 (en) * | 2015-09-17 | 2021-12-14 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
| EA201890941A1 (ru) * | 2015-10-23 | 2018-11-30 | Сорренто Терапьютикс, Инк. | Программируемые универсальные клеточные рецепторы и способы их применения |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| US20220008553A1 (en) * | 2015-11-23 | 2022-01-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof |
| CN107029244B (zh) * | 2016-02-04 | 2021-04-27 | 浙江昭华生物医药有限公司 | 抗her2抗体-药物偶联物及其应用 |
| US10329321B2 (en) | 2016-02-09 | 2019-06-25 | Alexander Krantz | Site-selective functionalization of proteins using traceless affinity labels |
| JP2019510078A (ja) * | 2016-02-23 | 2019-04-11 | セセン バイオ， インコーポレイテッド | Ｉｌ−６アンタゴニスト製剤およびその使用 |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
| CN110382535A (zh) | 2017-01-17 | 2019-10-25 | 第一三共株式会社 | 抗-gpr20抗体以及抗-gpr20抗体-药物缀合物 |
| BR112019015069A2 (pt) | 2017-01-24 | 2020-03-03 | Pfizer Inc. | Derivados de caliqueamicina e conjugados de anticorpo-fármaco dos mesmos |
| TW202530219A (zh) | 2017-05-15 | 2025-08-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| WO2019044946A1 (ja) | 2017-08-31 | 2019-03-07 | 第一三共株式会社 | 抗体－薬物コンジュゲートの新規製造方法 |
| JP7366745B2 (ja) | 2017-08-31 | 2023-10-23 | 第一三共株式会社 | 抗体－薬物コンジュゲートの改良製造方法 |
| WO2019090242A1 (en) * | 2017-11-04 | 2019-05-09 | Advanced Proteome Therapeutics Inc. | Composition and method for modifying polypeptides |
| CN111566126B (zh) | 2018-01-12 | 2024-11-12 | 美国安进公司 | Pac1抗体及其用途 |
| US12479926B2 (en) | 2018-05-18 | 2025-11-25 | Daiichi Sankyo Co., Ltd. | Anti-MUC1 antibody-drug conjugate |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| CN112805036A (zh) | 2018-07-31 | 2021-05-14 | 第一三共株式会社 | 通过施用抗体-药物缀合物对转移性脑肿瘤的治疗 |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EA202190416A1 (ru) | 2018-08-02 | 2021-06-23 | Дайн Терапьютикс, Инк. | Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| KR20220045047A (ko) * | 2019-08-19 | 2022-04-12 | 션양 파마슈티컬 유니버시티 | 항체 변이체 및 이의 적용 |
| US20220347312A1 (en) | 2019-09-04 | 2022-11-03 | Bolt Biotherapeutics, Inc. | Immunoconjugate Synthesis Method |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| WO2023288033A1 (en) | 2021-07-14 | 2023-01-19 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| AU2022377070A1 (en) * | 2021-11-01 | 2024-04-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes for treating dystrophinopathies |
| WO2023201324A1 (en) * | 2022-04-15 | 2023-10-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CN119183457A (zh) | 2022-04-15 | 2024-12-24 | 达因疗法公司 | 用于治疗强直性肌营养不良的肌肉靶向复合物和制剂 |
| CN117801107A (zh) | 2022-09-30 | 2024-04-02 | 上海迪诺医药科技有限公司 | 苯并氮杂卓衍生物、含其的偶联物及其应用 |
| AU2024229817A1 (en) | 2023-02-28 | 2025-08-14 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Chemical coupling linker and use thereof |
| CN118805740B (zh) * | 2024-08-07 | 2025-12-19 | 中国中医科学院中药研究所 | 一种人呼吸道合胞病毒感染小鼠重症肺炎动物模型的构建方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| CA2389250C (en) | 1999-10-08 | 2010-07-20 | The Scripps Research Institute | Antibody catalysis of enantio- and diastereo-selective aldol reactions |
| ES2344592T3 (es) | 2001-01-05 | 2010-09-01 | Pfizer Inc. | Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i. |
| JP4750360B2 (ja) | 2001-10-22 | 2011-08-17 | ザ スクリプス リサーチ インスティチュート | 抗体ターゲッティング化合物 |
| US7217845B2 (en) * | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| MXPA06001634A (es) | 2003-08-13 | 2006-04-28 | Pfizer Prod Inc | Anticuerpos humanos modificados igf-1r. |
| JP5167473B2 (ja) | 2005-03-03 | 2013-03-21 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管新生化合物 |
| DK2089425T3 (da) | 2006-11-10 | 2011-10-10 | Covx Technologies Ireland Ltd | Antiangiogene forbindelser |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| CA2697612A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-igf-1r antibodies and uses thereof |
| US20110189206A1 (en) | 2008-01-03 | 2011-08-04 | Barbas Iii Carlos F | Antibody Targeting Through a Modular Recognition Domain |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
-
2011
- 2011-07-11 CA CA2804185A patent/CA2804185C/en active Active
- 2011-07-11 PH PH1/2013/500070A patent/PH12013500070A1/en unknown
- 2011-07-11 RU RU2012157167/10A patent/RU2012157167A/ru not_active Application Discontinuation
- 2011-07-11 EP EP11745833.1A patent/EP2593142B8/en active Active
- 2011-07-11 SG SG2012094983A patent/SG186451A1/en unknown
- 2011-07-11 AR ARP110102486A patent/AR082205A1/es not_active Application Discontinuation
- 2011-07-11 PE PE2013000052A patent/PE20130643A1/es not_active Application Discontinuation
- 2011-07-11 WO PCT/IB2011/053092 patent/WO2012007896A1/en not_active Ceased
- 2011-07-11 AU AU2011277999A patent/AU2011277999A1/en not_active Abandoned
- 2011-07-11 BR BR112013000951A patent/BR112013000951A2/pt not_active Application Discontinuation
- 2011-07-11 MX MX2013000491A patent/MX2013000491A/es unknown
- 2011-07-11 ES ES11745833T patent/ES2704223T3/es active Active
- 2011-07-11 JP JP2013519199A patent/JP5913307B2/ja active Active
- 2011-07-11 CN CN2011800438472A patent/CN103096933A/zh active Pending
- 2011-07-11 KR KR1020137003413A patent/KR20130050966A/ko not_active Ceased
- 2011-07-12 TW TW100124612A patent/TWI432213B/zh not_active IP Right Cessation
- 2011-11-28 US US13/305,354 patent/US8741291B2/en active Active
-
2013
- 2013-01-07 ZA ZA2013/00161A patent/ZA201300161B/en unknown
- 2013-01-11 CO CO13004943A patent/CO6670522A2/es unknown
-
2015
- 2015-12-21 JP JP2015248537A patent/JP6339995B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013534535A5 (cg-RX-API-DMAC7.html) | ||
| Ma et al. | A review of the application of nanoparticles in the diagnosis and treatment of chronic kidney disease | |
| Haendler et al. | Recent developments in antiandrogens and selective androgen receptor modulators | |
| Abou-Antoun et al. | Brain cancer stem cells in adults and children: cell biology and therapeutic implications | |
| Spano et al. | Molecular networks that regulate cancer metastasis | |
| Azevedo et al. | Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review | |
| JP2010536719A5 (cg-RX-API-DMAC7.html) | ||
| Song et al. | Development of small molecules targeting the Wnt signaling pathway in cancer stem cells for the treatment of colorectal cancer | |
| JP2010532774A5 (cg-RX-API-DMAC7.html) | ||
| JP2011126896A5 (cg-RX-API-DMAC7.html) | ||
| JP2010209101A5 (cg-RX-API-DMAC7.html) | ||
| RU2016108667A (ru) | Комбинированная терапия для лечения рака | |
| RU2013134359A (ru) | Комбинированная терапия с применением индуктора и ингибитора аутофагии для лечения новообразований | |
| EP2170062A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES | |
| JP2011157399A5 (cg-RX-API-DMAC7.html) | ||
| JP2010516626A5 (cg-RX-API-DMAC7.html) | ||
| WO2007109347A3 (en) | N-cadherin and ly6 e: targets for cancer diagnosis and therapy | |
| JP2013541586A5 (cg-RX-API-DMAC7.html) | ||
| MX2021014524A (es) | Metodos para tratar canceres del sistema urinario. | |
| JP2013537228A5 (cg-RX-API-DMAC7.html) | ||
| JP2017536397A5 (cg-RX-API-DMAC7.html) | ||
| JP2014005265A5 (cg-RX-API-DMAC7.html) | ||
| WO2012170804A9 (en) | Treatments for gastrointestinal disorders | |
| CL2008003005A1 (es) | Uso de la etilamina del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-isoxazol-3-carboxilico, una sal, hidrato o solvato del mismo para preparar un medicamento util en el tratamiento de diferentes tipos de cancer. | |
| FR2910324B1 (fr) | Nouveau medicament pour le traitement d'un cancer gastrique |